Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)

NCT05063786 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Advanced Breast Cancer

Interventions

BIOLOGICAL: Trastuzumab
DRUG: Alpelisib
DRUG: Fulvestrant
DRUG: Vinorelbine
DRUG: Capecitabine
DRUG: Eribulin

Sponsor

Spanish Breast Cancer Research Group

Collaborators

[object Object]
[object Object]
[object Object]